1009 QTs
BioCentury & Getty Images

Product Development

Oct. 9 Quick Takes: Sobi’s Phase III miss; plus Alkermes, COVAX, Warp Speed-AZ, Lilly-Gates, Pfizer, Everest and Affamed-Kissei

Oct 10, 2020 | 12:20 AM GMT

Sobi’s avatrombopag misses in Phase III for chemotherapy-induced thrombocytopenia 
Swedish Orphan Biovitrum AB (SSE:SOBI) sank 18% on Friday, shedding $1.3 billion in market cap, after CD110 agonist Doptelet avatrombopag missed the composite primary endpoint in a placebo-controlled Phase III

Read the full 667 word article

How to gain access

Continue reading with a
two-week free trial.